ZY-001

ZY-001 (brand name Kamini) is an oral, CNS-targeted, modified-release formulation of disodium etidronate being developed by ZY Therapeutics. It is designed as a disease-modifying therapy to directly target and chelate pathological brain calcifications ('brain stones'), which are calcium-phosphate deposits that disrupt neuronal signaling and drive seizures, cognitive decline, and motor symptoms. ZY-001 utilizes a three-layer microgranule architecture—comprising a micro-encapsulated core of purified disodium etidronate, a penetration enhancer layer to facilitate blood-brain barrier transit, and an enteric coating to optimize intestinal absorption and reduce gastrointestinal irritation. The drug is currently in preclinical and IND-enabling development for rare central nervous system disorders characterized by brain calcifications, including Sturge-Weber Syndrome (SWS)-related epilepsy, Tuberous Sclerosis Complex (TSC), neurocysticercosis, and Fahr's disease.

Brand names

Kamini

Other names

disodium etidronateetidronateetidronate disodium